glp-1 therapy madisonville Buddy GLP 1 + GIP /

Your doctor may consider whether dose adjustment, temporary treatment interruption, or investigation for alternative causes is appropriate

Combining the therapeutic approaches of GLP-1 agonists (which target extrahepatic mechanisms for metabolic disorders) with resmetirom (which target intrahepatic mechanisms for MASH and liver fibrosis) seems like a promising strategy for addressing fat accumulation, inflammation, and fibrosis associated with MASH

Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al

Gastroenterology (2023) 164(2):22840

As noted above, GLP-1s are also a powerful tool in diabetes management